Rising Bioscience: Cannabis Aktie mit MK von 8 Mio $ - 500 Beiträge pro Seite

[strongbuyamitelo]

Wird Zeit, dass hier ein Thread eröffnet wird.

Rising India heißt seit letztem Jahr Rising Bioscience INC. Ein Symbolchange ist beantragt und steht aus.
Bei der Firma handelt es sich um ein Forschungs- und Entwicklungsunternehmen, welches u.a. schmerzlindernde Kapseln (TSW-Topicals) und Cannabis Kapseln mit je 30mg THC und 10mg CBD herstellt.

Hier die Homepage für nähere Infos:
https://www.risingbiosciences.org/

[strongbuyamitelo]

Hier die letzte PM:

Rising Biosciences, Inc. To Offer Cannophen™ to Patients in Ohio, Florida; Launches Initiatives for National Distribution of Scar Peptide SerumPress Release | 02/20/2018
SANDUSKY, Ohio, Feb. 20, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) -- Rising India, Inc.’s (OTC:RSII) -- Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it will partner with PAO Group’s (OTC:PAOG) Alternative Medicine Centers of America to offer a free trial of Cannophen™ to patients in the state of Ohio. Anyone with a valid Ohio recommendation can apply for the trial at our Ohio clinics; this will be done on a patient to patient basis.

Scar Peptide Serum results
Before and after surgery using Rising Bioscience’s Scar Peptide Serum to diminish scars


Cannophen JPG.jpg


Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.

“This is a monumental event for our company and one that means quite a bit to me personally,” states COO Arthur Hall. “I have been using Cannophen™ since its earliest development stages in hopes to explore and discover its beneficial properties. Initially I was taking for symptoms of Parkinson’s and was astounded by overall results: I had also been battling cancer for some time and through surgery, limited chemotherapy and the use of Cannophen™ I am now cancer free. My physicians are okay with the continued use of Cannophen™ for maintenance. We are grateful to be sharing this with other patients beginning with the program in Ohio I also will be meeting with a Producer/Processor in California next week that has demonstrated serious interest in licensing and distributing Cannophen™ and other Rising Biosciences products.”

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.

Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. One notable study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.

As well, Rising Biosciences is nearing completion on its FDA testing of the TSW (This Sh** Works) pain cream products and is currently working with a company for national distribution of its Scar Peptide Serum.

Rising Biosciences Scar Peptide Serum:

http://www.globenewswire.com/NewsRoom/AttachmentNg/e05261a1-…

The following image depicts a patient who used the serum post-surgery to diminish scars, to astounding results:

http://www.globenewswire.com/NewsRoom/AttachmentNg/ff82692d-…

Before and after surgery using Rising Bioscience’s Scar Peptide Serum to diminish scars

“Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opioids on America through the responsible use of cannabis”

$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

CONTACT INFO: 
For Investor Inquiries:
 [e-mail]

https://www.otcmarkets.com/stock/rsii/news/Rising-Bioscience…

[strongbuyamitelo]

Hier der letzte Quartalsbericht:

https://backend.otcmarkets.com/otcapi/company/financial-repo…

Daraus:

Shares Authorized 850,000,000 500,000,000
Shares Outstanding 499,115,348 387,145,348
Freely Tradable 358,396,690 158,396,690

Natürlich handelt es sich hier um einen OTC-Wert, also Totalverlust möglich. Das sollte jedem bewusst sein.

In den nächsten Tagen wird eine PM erwartet. Ein Facebookeintrag von gestern dazu reichte aus, dass der Kurs von 0,12 ct auf zwischendurch 0,18 ct hochschnellte, was das enorme Potential der Aktie aufzeigt. Hier der Eintrag:

Rising BioSciences, Inc.
14 Std. ·
Hello everyone we are back in Ohio from a great trip to the the west coast and are pleased to announce that we are working on contracts with multiple producers and processors in both California and Arizona for multiple products please stay tuned for an official PR in a few days

https://www.facebook.com/RisingBioSciences/

Mal schauen, wo die Reise hingeht. Ich bin vor drei Tagen zu durchschnittlich 0,146 ct. eingestiegen


Good luck to all!

[strongbuyamitelo]

Antwort auf Beitrag Nr.: 57.284.032 von strongbuyamitelo am 15.03.18 08:29:46

1,2ct auf 1,8 ct natürlich...

[strongbuyamitelo]

[strongbuyamitelo]

Antwort auf Beitrag Nr.: 57.285.898 von strongbuyamitelo am 15.03.18 11:08:16

http://stockcharts.com/h-sc/ui?s=rsii

[strongbuyamitelo]

Antwort auf Beitrag Nr.: 57.285.919 von strongbuyamitelo am 15.03.18 11:09:15

[strongbuyamitelo]

Lief gestern fast bis auf das 52 Wochen Hoch (2,15ct), SK bei 1,95 ct.
Durch die langen Dochte oben und unten, verbunden mit dem mehrtägigen Anstieg könnte es heute ins Minus drehen, es sei denn die erwartete PM wird veröffentlicht.
Wird übrigens eine Absichtserklärung sein (wurde zumindest auf Facebook gepostet).

[strongbuyamitelo]

Aktuelle Empfehlung:

Rising India Inc (OTCMKTS:RSII) is Mounting its Case to Bring CBD Oil to the Pharma World
By Gene Daniel - March 15, 2018
SHARE Facebook Twitter
Rising India Inc (OTCMKTS:RSII) is running once again. RSII is up more than 120% over the last month. The cannabis company is still seeing some burn from their news in February that saw patients in Ohio receive a free trial of their oral capsule, Cannophen.

Cannophen is designed to help a patient recover from smoking and vaping, but the drug has beneficial elements and it’s effective in treating Parkinson’s symptoms, cancer, and other chronic medical conditions. More specifically, the product is a tablet with measured lab dosages that may be ground in equal portions of CBD, THC and strain-specific terpenes. The product is easily digested, quick acting and created for patients who do not want to smoke or deploy off tasting tinctures. In fact, RSII’s COO used Cannophen to become cancer free. COO Arthur Hall stated in a previous release: “I have been using Cannophen since its earliest development stages in hopes to explore and discover its beneficial properties. Initially, I was taking for symptoms of Parkinson’s and was astounded by overall results: I had also been battling cancer for some time and through surgery, limited chemotherapy and the use of Cannophen I am now cancer free. My physicians are okay with the continued use of Cannophen for maintenance.”

Rising India Inc (OTCMKTS:RSII) bills itself as a new and emerging player in the cannabis patch.

The company had been trumpeting itself as “a publicly traded United States company that seeks to accelerate growth through possible joint ventures, mergers, and/or new acquisitions pertaining to development and deployment of media.” The company actually incorporated on April 29, 1998, as a media holding company – an animation company working to develop and market various international media projects. The Company has announced acquisitions, joint-ventures and/or mergers with operating film and media operations pertaining to support and transactional businesses within the film and media industry.

Recently, as noted above the company entered into the cannabis industry wholly and completely via a reverse merger with Rising BioSciences, Inc., which is now the company in charge of the RSII ticker as far as we can determine.

Find out when $RSII stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.





Furthermore, and this is the impetus behind their brand, ‘cannabinoids’ in marijuana have been shown to slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.

Meanwhile, on another front, RSII is nearing completion on the approval of the TWS pain cream products and it’s in the process of partnering with a firm for national distribution of Scar Peptide Serum. The company focuses on producing oral and topical cannabis and non-cannabis-based products using standards set by the pharmaceutical industry.

Earning a current market cap value of $8.49M, RSII has a very high gearing ratio, with a large swathe of its liabilities a result of long-term debts which are likely to accrue interests. Its low liquidity of 0.03 means RSII is expected to raise new cash soon, except it can beef up its revenues in time to meet up borrowing and operating costs. Sign-up for continuing coverage on shares of $RSII stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $RSII, either long or short, and we have not been compensated for this article.


https://oracledispatch.com/2018/03/15/rising-india-inc-otcmk…

[strongbuyamitelo]

Artikel vom 18.3.:

The moment medical marijuana has been waiting for since California first passed laws legalizing the medicinal use of cannabis, in 1996, is finally here — the US government has, at last, admitted that marijuana has medical benefit. Yes, you heard right — the US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about, cannabis and cannabinoids.

Attempting to not draw too much attention to the update, the US National Cancer Institute quietly updated their website in January, admitting that cannabis and cannabinoids kill cancer without damaging the body’s normal cells. Considering that cannabis is a Schedule 1 drug, which according to the Controlled Substances Act of 1970, means that it holds NO MEDICINAL VALUE, how could such a unbelievable admission go unnoticed by mainstream media? After all this is the plant that has been demonized as the “gateway drug”, for the past 80 years — this is BREAKING NEWS!!

The pages include a section for both patients, and physicians, and covers topics ranging from the medical effects of cannabinoids, to preclinical studies conducted using cannabis or cannabinoids. Studies in mice and rats have shown that cannabinoids may inhibit the growth of a tumor by causing cell death, blocking cell growth, and blocking the development of blood vessels need by tumors to grow. While further animal and laboratory study’s have shown evidence that cannabinoids may be able to kill cancer cells while protecting normal cells.

Additional studies have shown that there is evidence of cannabinoids protecting against inflammation and cancer of the colon; may have anti-tumor effects; may be effective in stoping breast cancer; and may make chemotherapy more effective.

Also included, is commentary about how the US government distributed cannabis to patients on a case-by-case basis under the Compassionate Use Investigational Drug (IND) program between 1978 and 1992, despite while claiming that cannabis held no medicinal value. It goes on further to say that researchers, have studied how cannabinoids act on the brain and other parts of the body, and have discovered cannabinoid receptors (molecules that bind cannabinoids) in both brain cells, and nerve cells in other parts of the body, with further evidence of cannabinoid receptors on immune system cells, suggesting that cannabinoids may play a key role in immunity, too.

It also includes information on its effectiveness to stimulate an appetite, relieve pain, reduce inflammation, control nausea and vomiting, it’s anti-anxiety effects.



Since the early 1990’s physicians have been prescribing opioid medications at an ever-increasing, and alarming rate. Resulting in an epidemic far greater in evil, than any reefer madness. The US, is now battling to counter the out-of-control, critical state of prescription drug abuse that is plaguing all classes, ethnicities, and ages. It is estimated that 52 million people have used prescription pills for non-medical reasons at least once in their lifetime, including a overwhelming large number of young people. The National Institute on Drug Abuse (NIDA) conducted a survey called “Monitoring the Future”, which found that 1 in 12 high school seniors reported non-medical use and abuse of prescription pills, while rating Vicodin, and OxyContin, as the most commonly abused drugs by adolescents. In an effort to regain control of the pill-popping monster that has been pharmaceutically created, the US is clamping down on the physicians who have writing the prescriptions, enforcing a strict new protocol that is leaving only pain management physicians with the right to prescribe pain pills.

Which leaves us to wonder only one thing – could the federal government be getting ready to reschedule cannabis, allowing for the medical research and scientific study of pot?

Firstly as a solution, to curbing the pandemic of prescription abuse among people, and patients. Secondly as a peace offering, to the pharmaceutical super-giants grotesquely over-capitalizing on the current state of the nation — cannabis will open the door to a whole new pharmaceutical industry as compensation, and while this is not something we condone, the simple fact alone is enough to have the ensure that pharmaceutical lobbyists share our agenda. Thirdly, because President Obama promised to support and sign the CARERS ACT, legalizing the medicinal use of marijuana thereby allowing for its use by the Veterans Affairs, and the vets who repeatedly keep pleading for reform — Question: Why are our vets pleading? They are our veterans, the men and women who have risked their lives, to defend and protect ours. They shouldn’t need to ask – let alone still beg or plead! As a nation, we should respectfully give them anything they need to help ease their pain and suffering, as a result of their service.

And finally – and most importantly of all – because President Obama promised change, and congressional reform of medical cannabis if the states led the way. Considering that when Obama took office in 2009 there were already 14 legal medical marijuana states, and now there’s 23 with more on the way, while 4 states and the District of Columbia have altogether legalized the recreational adult-use of pot, its clear that the states have held up their end. Now, its time for the president to uphold his.

“I don’t think rescheduling is something that I would characterize as drastic,” said U.S. Rep. Earl Blumenauer (D-Oregon), one of the key members of Congress’s cannabis reform cabal. “If we were scheduling today, marijuana would not be Schedule I — or Schedule II. In fact, it may not be scheduled at all.”

“If we were scheduling from scratch and doing so based on scientific evidence, tobacco would be Schedule I. It’s an addictive killer,” he added

http://urhealthguide.com/breaking-news-us-govt-admits-cannab…

[strongbuyamitelo]

52-Wochen Hoch. Aktuell 2,4ct.

[strongbuyamitelo]

Wahnsinn!! SK 2.8 ct. Allzeithoch und 40% plus heute. Bin begeistert. Gegen Ende wurde ein 3 Mio Block aus dem ask weggekauft.
Im amerikanischen Board uüberschlägt man sich, hier ist tote Hose.

[strongbuyamitelo]

SANDUSKY, Ohio, March 20, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) --Rising India, Inc.’s (OTC:RSII) -- Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it has launched near-term initiatives to expedite growth for long-term shareholder value.

We are thrilled to announce that Rising Biosciences will also be rolling out its RBS0238 CLINICAL PEPTIDE SERUM (our scar serum) in Q2. “We could not be more excited to announce that after a recent meeting with the manufacturer of our clinical strength peptide serum, we are officially entering production phase for the product line and it will be on sale, available for national distribution, in late April/early May,” states Hall. “This means revenues, revenues and more revenues.”

“As well, we have corresponded in regards to the FDA testing procedures on our TSW pain cream and they continue to progress to what we feel will be near-term completion.”

The Company has also recently hired a seasoned chemist who will serve as Chief Chemist in-house at the Company’s Ohio Laboratory. COO Arthur Hall states, “Our Chief Chemist will be traveling to Florida to train with our staff there on overall procedures and protocol. We are thrilled to have secured talent at this level which will greatly expedite research and development on new product ideas as well as staff expertise in all of our locations.”

“As well, we have purchased analytical equipment which will allow us to do developmental testing on-site as opposed to the costly and timely procedure of shipping to an outside laboratory. The equipment is paid for and scheduled to be installed next week.”

The Company also announces updates on expansion and have entered into contracting stages with two California Producer/Processors, one of which also has operations and facilities in Arizona for manufacturing Cannophen™ and TSW pain cream with CBD/THC. A Producer/Processor grows or extracts (THC, CBD, etc.) directly from flower and also processes and manufactures MMJ products. “We anticipate this to effect a near-term multiplier regarding overall operations and potential revenues.”

“The Medical Marijuana revolution has only begun,” states Hall. “The US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about cannabis and cannabinoids.”

The new updates, implemented in January, include information indicating that cannabis and cannabinoids can kill cancer without damaging the body’s normal cells.

The National Cancer Institute states a number of facts about Antitumor activity and pain relief, among others, citing studies in mice and rats which have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. As well, it goes on to state that A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.

“We are on the cusp of something fantastic here and are grateful for continued shareholder participation. We are developing life-changing products and anticipate continued shareholder value alongside assertive R&D initiatives, partnerships and acquisitions as well as both B2B and B2C sales strategies for our product lines,” concludes Hall.

Hall is planning trips to Colorado and Michigan in the coming weeks to meet with producers and processors in those markets, among others on the company’s agenda.

“Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis”

$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

CONTACT INFO:
For Investor Inquiries:
[e-mail]

http://www.globenewswire.com/news-release/2018/03/20/1443055…